| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues, net | 214,539 | -151,117 | 635,224 | 178,238 |
| Cost of implants and other costs | NaN | -337,010 | 358,812 | 0 |
| Cost of goods sold | 25,184 | NaN | NaN | NaN |
| Research and development | 352,333 | 305,516 | 1,004,660 | 296,860 |
| Selling, general and administrative | 775,453 | 539,369 | 1,145,353 | 1,223,321 |
| Impairment of intellectual property | 6,374 | NaN | NaN | NaN |
| Depreciation and amortization | 11,195 | -124,803 | 71,986 | 71,977 |
| Total operating expenses | 1,170,539 | 383,072 | 2,580,811 | 1,592,158 |
| Other miscellaneous income | NaN | NaN | NaN | 104,890 |
| Loss from operations | -956,000 | -534,189 | -1,945,587 | -1,413,920 |
| Interest expense - related parties | 135,448 | 437,947 | 195,515 | 164,371 |
| Interest expense, net | 31,041 | 70,009 | 29,672 | 36,686 |
| Loss on settlement of debt | -100,000 | 0 | 0 | -55,000 |
| Grant income | 362,597 | 903,748* | 867,130 | 154,270 |
| Change in fair value of upfront purchase price liability | 0 | -4,157.5* | -1,785 | -394 |
| Change in fair value of royalty liability | 0 | -330,413.5* | 0 | 33,935 |
| Other miscellaneous income | 0 | 1,747* | 496,927 | NaN |
| Total other income | 96,108 | 62,968 | 1,137,085 | 36,644 |
| Loss before provision for income taxes | -859,892 | -471,221 | -808,502 | -1,377,276 |
| Income taxes | 0 | 0 | NaN | 0 |
| Net loss | -859,892 | -471,221 | -808,502 | -1,377,276 |
| Non-controlling interest | -28,665 | -1,023,773 | -1,109,371 | -143,858 |
| Net gain attributable to biocorrx inc | -831,227 | 552,552 | -1,917,873 | -1,233,418 |
| Basic EPS | 0.34 | NaN | NaN | NaN |
| Diluted EPS | -0.03 | 0.03 | -0.11 | -0.07 |
| Basic Average Shares | NaN | NaN | NaN | 17,011,680 |
| Diluted Average Shares | 25,599,642 | 18,485,888* | 18,162,783 | NaN |
BioCorRx Inc. (BICX)
BioCorRx Inc. (BICX)